Join Brad Davis, a principal at Norstella, and Fenwick Eckhardt, head of diversity strategy at Citeline, for an in-depth look at the FDA's guidance on Diversity Action Plans.
In this webinar, explore the intricacies of developing effective Diversity Action Plans for clinical trials. Learn about the FDA's expectations, including required studies, essential components of each plan, and enrollment goals for diverse populations, alongside the importance of timely submission and the potential consequences of non-compliance. The session will provide practical examples and insights tailored to different therapeutic areas, highlighting why a standardized approach may not be sufficient.
Brad Davis
Principal, Consulting & Analytics, Citeline
Brad Davis is a Principal at Norstella with a depth of experience deriving actionable insights from Real-World Data (RWD). Brad has been in the pharmaceutical industry for 20+ years spanning clinical development, management consulting, and communications. This unique blend of clinical and commercial expertise including clinical trial strategy and design, patient recruitment, portfolio optimization, and commercial launch strategy allows for an innovative approach to problem solving. He has significant experience across therapeutic areas, particularly psychiatry, neurology, oncology, immunology, and rare diseases.
Fenwick Eckhardt
Head of Diversity Strategy, Citeline
Fenwick Eckhardt is head of diversity strategy at Citeline. She is dedicated to revolutionizing the life sciences industry through cutting-edge solutions that harness real-world data, technology, and analytics. With over five years of experience in pharma and biotech, Fenwick excels in optimizing clinical trial design and outcomes to expedite the delivery of life-saving therapies. She holds a master’s degree from Imperial College London and a bachelor’s in human physiology from Boston University.